Related Experiment Video
Updated: Mar 7, 2026
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Anti-Inflammatory Activity of Sanghuangporus sanghuang Mycelium
Wang-Ching Lin1, Jeng-Shyan Deng2, Shyh-Shyun Huang3
1School of Pharmacy, China Medical University, Taichung 404, Taiwan. linwc0913@gmail.com.
Abstract:
Acute lung injury (ALI) is characterized by inflammation of the lung tissue and oxidative injury caused by excessive accumulation of reactive oxygen species. Studies have suggested that anti-inflammatory or antioxidant agents could be used for the treatment of ALI with a good outcome. Therefore, our study aimed to test whether the mycelium extract of Sanghuangporus sanghuang (SS-1), believed to exhibit antioxidant and anti-inflammatory properties, could be used against the excessive inflammatory response associated with lipopolysaccharides (LPS)-induced ALI in mice and to investigate its possible mechanism of action. The experimental results showed that the administration of SS-1 could inhibit LPS-induced inflammation. SS-1 could reduce the number of inflammatory cells, inhibit myeloperoxidase (MPO) activity, regulate the TLR4/PI3K/Akt/mTOR pathway and the signal transduction of NF-κB and MAPK pathways in the lung tissue, and inhibit high mobility group box-1 protein 1 (HNGB1) activity in BALF. In addition, SS-1 could affect the synthesis of antioxidant enzymes Heme oxygenase 1 (HO-1) and Thioredoxin-1 (Trx-1) in the lung tissue and regulate signal transduction in the KRAB-associated protein-1 (KAP1)/nuclear factor erythroid-2-related factor Nrf2/Kelch Like ECH associated Protein 1 (Keap1) pathway. Histological results showed that administration of SS-1 prior to induction could inhibit the large-scale LPS-induced neutrophil infiltration of the lung tissue. Therefore, based on all experimental results, we propose that SS-1 exhibits a protective effect against LPS-induced ALI in mice. The mycelium of S. sanghuang can potentially be used for the treatment or prevention of inflammation-related diseases.
Insights
Mycelium extract of Sanghuangporus sanghuang (SS-1) effectively treats lipopolysaccharides (LPS)-induced acute lung injury (ALI) in mice by reducing inflammation and oxidative stress. SS-1 demonstrates protective effects via multiple molecular pathways, suggesting potential for treating inflammatory lung diseases.
Area of Science:
- Pharmacology
- Immunology
- Biochemistry
Background:
- Acute lung injury (ALI) involves lung inflammation and oxidative stress.
- Anti-inflammatory and antioxidant agents show promise for ALI treatment.
Purpose of the Study:
- To evaluate the efficacy of Sanghuangporus sanghuang mycelium extract (SS-1) against lipopolysaccharides (LPS)-induced ALI in mice.
- To investigate the underlying molecular mechanisms of SS-1's action.
Main Methods:
- Mice were induced with LPS to model ALI.
- SS-1 administration was assessed for its effects on inflammatory markers, cellular infiltration, and molecular pathways.
- Key pathways investigated included TLR4/PI3K/Akt/mTOR, NF-κB, MAPK, and Nrf2/Keap1.
Main Results:
- SS-1 significantly inhibited LPS-induced inflammation and neutrophil infiltration in lung tissue.
- SS-1 modulated the TLR4/PI3K/Akt/mTOR, NF-κB, and MAPK signaling pathways.
- SS-1 regulated the Nrf2/Keap1 pathway, influencing antioxidant enzyme synthesis (HO-1, Trx-1) and inhibiting HMGB1 activity.
Conclusions:
- SS-1 exhibits significant protective effects against LPS-induced ALI in mice.
- SS-1's therapeutic potential lies in its ability to suppress inflammatory responses and oxidative stress through multiple molecular targets.
- The mycelium of S. sanghuang may be a valuable resource for developing treatments for inflammatory diseases.
